[Androgen deprivation therapy in advanced prostate cancer. Multicenter study.]

Autor:	Valencia-Guadalajara VJ; Hospital Universitari Sant Joan d'Alacant. Alicante. España., Martínez-Cayuelas L; Hospital Universitario del Vinalopó. Elche.Alicante. España., Sarrió-Sanz P; Hospital Universitari Sant Joan d'Alacant. Alicante. España., Sánchez-Caballero L; Hospital Universitari Sant Joan d'Alacant. Alicante. España., Polo-Hernández R; Hospital General Universitario de Alicante. Alicante. España., Chillón-Sempere FS; Hospital General Universitario de Alicante. Alicante. España., Galán-Llopis JA; Hospital General Universitario de Alicante. Alicante. España., Garcés-Valverde M; Hospital Universitario del Vinalopó. Elche.Alicante. España., Tenza-Tenza JA; Hospital Virgen de los Lirios. Alcoy. Alicante. España., Costa-Martínez A; Hospital General Universitario de Elche. Alicante. España., García Serrado-Paumard D; Hospital General Universitario de Elda. Alicante. España., Escudero-Fontana E; Hospital Vega Baja. Orihuela. Alicante. España., Tello-Royloa C; Hospital Vega Baja. Orihuela. Alicante. España., Verdú-Verdú LP; Hospital Marina Baixa. Villajoyosa. Alicante. España., Bravo-López DF; Hospital Marina Baixa. Villajoyosa. Alicante. España., Pérez Seoane-Ballester H; Hospital Universitari Sant Joan d'Alacant. Alicante. España., Pacheco-Bru JJ; Hospital Universitari Sant Joan d'Alacant. Alicante. España., Ortiz-Gorraiz MÁ; Hospital Universitari Sant Joan d'Alacant. Alicante. España.
Jazyk:	Spanish; Castilian
Zdroj:	Archivos espanoles de urologia [Arch Esp Urol] 2020 Jul; Vol. 73 (6), pp. 499-508.
Abstrakt:	Objectives: Advanced prostate cancer (PC) is a frequent entity. The objectives of this paper are the presentation of a sample of patients with PC undergoing treatment with androgen deprivation therapy (ADT) in usual clinical practice and the determination of parameters associated with the development of resistance to castration (CRPC). Material and Methods: Multicenter, observational, retrospective study that analyzes patients treated with ADT from January 2016 to January 2017. Descriptive analysis of the most relevant clinical variables and univariante analysis and progression times by Kaplan-Meier test. Results: Sample of 952 patients. At PC diagnosis median age 74 years. Median PSA at PC diagnosis 23 ng/ml, when begining ADT 20.2 ng/ml. 80.2% of patients were biopsied at PC diagnosis: 28.2% Gleason score group 1, 38.7% groups 2 and 3 and 33.1% groups 4 and 5. Initial treatment of PC: 75.9% ADT, radical prostatectomy 8.4% and radiotherapy 15.1%. Of the 952 patients, 281 (29.6%) fulfilled CRPC criteria.In this group 21.7% achieved undetectable PSA (group in which it was 59.9%. Increased probability of progression to CRPC in: PSA >30ng/ml at PC diagnosis (p=0.000, OR 2.78), Gleason score group 4-5 (p=0.000, OR 2.33), and not to reach undetectable PSA after ADT (p <0.001, OR 3.32). The initial ADT group presents progression to metastatic CRPC more rapidly in unfavourable histology and when not reached undetectable PSA after ADT. Conclusions: We present a sample of patients with advanced PC in treatment with ADT that shows heterogeneity in usual clinical practice. In our sample, elevated PSA at PC diagnosis, unfavorable histology and failure to achieve a PSA<0.1 ng/ml after ADT is presented as an indicator of progression to the CRPC stage.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu